Patents Examined by Nita Minnifield
  • Patent number: 7033774
    Abstract: Polyclonal antibodies can be produced that reacts with recombinant EPO and its degradation products but not with native EPO. This antibody precipitation can be used to identify those glycopeptides that are uniquely reactive. These glycopeptides can be produced on preparative scale and used in the production of monoclonal antibodies which are screened against the original EPO and glycopeptides to select antibodies reactive to the specific glycopeptides an recombinant EPO but not to native human EPO. The monoclonal antibodies so selected are incorporated in a conventional ELISA and used to monitor urine and other bodily samples taken from athletes, either human or animal, and patients for presence and level of recombinant peptides or proteins. Alternatively, the polyclonal antibody can be used directly to produce ELISA tests.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 25, 2006
    Assignee: Glycozyme, Inc.
    Inventor: Allen K. Murray
  • Patent number: 7005270
    Abstract: Methods for the specific and highly sensitive detection of Treponema pallidum infection comprising the use of specific antigenic proteins and peptides unique to Treponema pallidum are provided. In particular, detection assays based recognition of acidic repeat protein are provided. The methods of the present invention are useful for detection of primary syphilis at early stages of infection. In addition, the methods and compositions disclosed herein are directed to the differential detection of specific Treponema infections enabling the identification of causative agents for specific Treponema disease states: syphilis (Treponema pallidum subspecies pallidum), yaws (Treponema pallidum subspecies pertenue CDC-1 or CDC-2 strain), and bejel (Treponema pallidum subspecies endemicum).
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: February 28, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hsi Liu, Bret M. Steiner, Berta Rodes
  • Patent number: 6998242
    Abstract: A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10?7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: February 14, 2006
    Assignee: Sankyo Co., Ltd.
    Inventors: Kazuki Yano, Fumie Kobayashi, Masaaki Goto, Naohiro Washida, Eisuke Tsuda, Kaoji Higashio, Yoshiji Yamada
  • Patent number: 6969616
    Abstract: The present invention is directed to an enterotoxin adsorbent comprising a compound having a log P (P denotes a partition coefficient in an octanol-water system) value of not less than 2.50 as immobilized on a water-insoluble carrier.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: November 29, 2005
    Assignee: Kaneka Corporation
    Inventors: Fumiyasu Hirai, Tamiji Fujimoto, Shigeo Furuyoshi
  • Patent number: 6951652
    Abstract: A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: October 4, 2005
    Assignee: BioSynth S.r.l.
    Inventor: Massimo Porro
  • Patent number: 6951845
    Abstract: The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen into the host. The antigen-encoding polynucleotides are administered to host tissues which contain a high concentration of antigen presenting cells (e.g., skin and mucosa) relative to other host tissues. Expression of the asthma-initiating antigen encoding polynucleotides of the invention inside of antigen presenting cells (without substantial secretion therefrom) induces antigen tolerance while suppressing IgE antibody formation in the early phase of the disease, and also suppresses cytokine-mediated eosinophil accumulation in the late phase of the disease. Devices and compositions for use in the methods of the invention are also described.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: October 4, 2005
    Assignee: The Regents of the University of California
    Inventors: Dennis A. Carson, Eyal Raz
  • Patent number: 6939549
    Abstract: Vaccines and methods useful to induce an immune response which is protective to reduce the severity or prevent infection by ehrlichial parasites of the species Anaplasma marginale utilizing recombinant MSP1a surface protein antigens alone or in combination with tick cell culture derived A. marginale.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: September 6, 2005
    Assignee: The Board of Regents for Oklahoma State University
    Inventors: Jose de Jesus de la Fuente, Katherine M. Kocan, Jose Carlos Garcia-Garcia, Edmour F. Blouin
  • Patent number: 6936258
    Abstract: A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: August 30, 2005
    Assignee: NABI Biopharmaceuticals
    Inventors: Viliam Pavliak, Ali Ibrahim Fattom
  • Patent number: 6936263
    Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 30, 2005
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Hilde Revets, Pierre Cornelis, Patrick De Baetselier
  • Patent number: 6902906
    Abstract: The invention provides a bacterium attenuated by a non-reverting mutation in each of the aroC gene, the ompF gene and the ompC gene. The bacterium is useful as a vaccine. The bacterium may, for example, be an attenuated strain of E. coli useful in vaccination against diarrhoea.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: June 7, 2005
    Assignee: Acambis Research Limited
    Inventor: Steven Neville Chatfield
  • Patent number: 6869937
    Abstract: Nucleic acid compositions encoding novel ACAT proteins, as well as the novel ACAT-2 proteins, (ACAT-2) are provided. Also provided are methods of producing the subject nucleic acid and protein compositions. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including diagnostic and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with ACAT-2 activity, e.g., in the treatment of gall stones.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: March 22, 2005
    Assignees: The Regents of the Universtiy of California, The United States of America as represented by the Department of Veteran Affairs
    Inventors: Sylvaine Cases, Robert V. Farese, Jr., Sandra K. Erickson, Sabine Novak, Michel Accad
  • Patent number: 6863891
    Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: March 8, 2005
    Assignee: Zentaris AG
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
  • Patent number: 6861510
    Abstract: Immmunogenic compositions useful for the treatment of ulcers or tumors whose growth is dependent on or stimulated by gastrin hormones are disclosed. The immunogenic compositions induce antibodies in a subject which selectively neutralize the specific hormones. Pharmaceutical compositions comprising effective amounts of the immunogenic compositions and methods of treatment using the compositions are disclosed. A method of reversing the inventive treatments by neutralizing the antibodies induced in vivo is also disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 1, 2005
    Assignee: Aphton Corporation
    Inventors: Philip C. Gevas, Stephen L. Karr, Stephen Grimes, Richard L. Littenberg
  • Patent number: 6861247
    Abstract: Substantially pure Salmonella secreted proteins (Ssp), the sercetion of which is dependent upon the expession of PrgH; methods of diagnosing Salmonella infection; and live attenuated vaccine strains in which Ssp secretion is decreased.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: March 1, 2005
    Assignee: The General Hospital Corporation
    Inventor: Samuel I. Miller
  • Patent number: 6828416
    Abstract: A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of parasite Plasmodium falciparum. The protein is useful as a reagent and, when combined with a pharmaceutically-acceptable vehicle or carrier, is useful as a vaccine against the material parasite Plasmodium falciparum. A genetic construct used to produce this recombinant protein vaccine is also described. In addition, antibodies to this recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: December 7, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Altaf A. Lal, Ya Ping Shi, Seyed E. Hasnain
  • Patent number: 6800727
    Abstract: The present invention relates to novel peptides with increased + charge and hydrophobicity by substituting one or more amino acids of CA-MA peptide in which cecropin A (CA) and magainin 2(MA) were conjugated and pharmaceutical compositions containing thereof. More precisely, the present invention relates to synthetic peptides prepared by substituting one or more amino acids of CA-MA peptide represented by the SEQ. ID. NO: 1 with amino acids having + charge and hydrophobicity and anti-bacterial, anti-fungal and anticancer compositions containing thereof. The synthetic peptides of the present invention have no cytotoxicity but have excellent anti-bacterial, anti-fungal and anticancer activity, leading in an effective use thereof as a safe anticancer agent and antibiotics.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: October 5, 2004
    Assignee: Chosun University
    Inventors: Kyung-Soo Hahm, Dong Gun Lee, YoonKyung Park
  • Patent number: 6793923
    Abstract: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: September 21, 2004
    Assignee: Immunovaccine Technologies, Inc.
    Inventors: Robert George Brown, William Pohajdak, Warwick Charles Kimmins
  • Patent number: 6794156
    Abstract: A competitive assay to determine the presence and concentration of an intracellular analyte (e.g., cAMP) in a sample is provided. All of the steps of the assay can be performed on the same assay plate, thereby eliminating the need to transfer the cells from a tissue culture plate on which the cells are grown, induced and lysed to a separate assay plate. The assay procedure includes combining, in a reaction chamber provided with a capture antibody, an antibody for the analyte, the sample to be assayed, and a conjugate of the analyte and an enzyme such as alkaline phosphatase. The mixture is incubated and washed and an enzyme labile substrate (e.g., a chemiluminescent, fluorescent or calorimetric substrate) is added. The assay can also be performed with a tagged analyte (e.g., an analyte having a radioactive or fluorescent tag) instead of an enzyme conjugate.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Applera Corporation
    Inventor: Anthony C. Chiulli
  • Patent number: 6764838
    Abstract: The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: July 20, 2004
    Assignee: University of Iowa Research Foundation
    Inventors: Joel V. Weinstock, David E. Elliott
  • Patent number: 6756041
    Abstract: A process for preparing a protein-polysaccharide conjugate includes reacting a protein with a polysaccharide to produce a mixture including a protein-polysaccharide conjugate and free protein. At least one unreacted reagent or low molecular weight component is removed from this mixture, without removing all of the free protein, to provide a purified mixture that contains the protein-polysaccharide conjugate and free protein. This purified mixture can be used as a conjugate vaccine, immunogen, or immunological reagent. Keeping the free protein in the purified mixture with the conjugate saves time and money in the conjugate production process. In another aspect of the invention, the purified mixture of the protein-polysaccharide conjugate and free protein is reacted with a hapten to produce a conjugate mixture including a hapten-protein conjugate and a hapten-protein-polysaccharide conjugate.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: June 29, 2004
    Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Andrew Lees, James Mond